Kuros Biosurgery AG, a Zurich, Switzerland-based biotechnology company, raised an additional CHF5m in a second closing of its financing round.
The total funding raised in the round now amounts to CHF20m. The first close of the financing announced in August was led by LifeCare Partners, and Life Sciences Partners as new investors with participation of non-disclosed family offices from Germany and Switzerland. Omega Funds, a Boston based life sciences-focused fund, also became a shareholder during the round, which was also supported by existing investors including VI Partners, Venture Incubator, and The Swiss Helvetia Fund, Inc.
Backers included a group of non-disclosed new and existing investors.
The company will use these additional funds to further accelerate its efforts to bring their sealant products to market and to progress their lead orthobiologics product into the final stage of clinical testing.
Led by Didier Cowling, Chief Executive Officer, Kuros develops novel biomaterials and bioactive-biomaterial combination products focusing on therapeutic areas covering sealants and orthobiologics. The company’s most advanced sealant product candidate is KUR-023, a sealant that has completed European clinical development and is close to being CE Marked. KUR-111 and KUR-113, Kuros’ most advanced orthobiologic products have both met the primary endpoints in large well controlled Phase II clinical studies and are progressing towards Phase III.
FinSMEs
11/11/2015